Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).
Pengxin Zhang, DaQuan Wang, Wenzhuo He et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II randomized controlled trial evaluated the efficacy and safety of toripalimab consolidation after chemoradiotherapy in patients with limited-stage small cell lung cancer (LS-SCLC). A total of 98 patients were randomized to receive either toripalimab or observation. The median progression-free survival (PFS) was not reached in the toripalimab group, while it was 14.1 months in the observation group (HR, 0.55).
Key findings
- Objective response rate was 60.9% in the toripalimab group versus 37.5% in the observation group.
- Median PFS was not reached in the toripalimab group compared to 14.1 months in the observation group (HR, 0.55).
- Median overall survival (OS) was not reached with toripalimab, while it was 30.3 months with observation (HR, 0.39).
- Treatment-related toxicities were generally mild, with 12.5% of patients in the toripalimab group discontinuing due to adverse events.
Why it matters
The integration of immunotherapy with chemoradiotherapy may enhance survival outcomes in limited-stage small cell lung cancer, a population with historically poor prognosis. These findings suggest a potential new treatment strategy that could improve patient outcomes.